Comprehensive and Deep Profiling in Cutaneous Squamous Cell Carcinomas to Unravel Treatment Efficacy in Immunotherapy Treated Patients
Latest Information Update: 25 Nov 2024
At a glance
- Drugs Cemiplimab (Primary)
- Indications Carcinoma; Head and neck cancer; Skin cancer; Squamous cell cancer
- Focus Pharmacodynamics; Pharmacogenomic
- Acronyms DISCERN
- 14 Aug 2024 Status changed from recruiting to active, no longer recruiting.
- 25 Oct 2023 Status changed from not yet recruiting to recruiting.
- 30 May 2023 New trial record